Equillium

Historical price data

Equillium is a public, clinical-stage biotech focused on developing first-in-class therapeutics that selectively modulate the immune system to treat severe autoimmune and inflammatory conditions. Its strategy is built on two core platforms: a Multi-Cytokine Inhibitor platform centered on itolizumab (EQ001) and an Aryl Hydrocarbon Receptor (AhR) modulation platform with EQ504. The company is actively advancing its lead candidate, itolizumab, in Phase 1b trials for aGVHD and lupus/lupus nephritis, targeting significant market opportunities with a differentiated mechanism designed to avoid broad immunosuppression.

Two core platforms: 1) A Multi-Cytokine Inhibitor platform generating structured-domain peptides and antibodies (e.g., itolizumab targeting CD6) to selectively modulate pathogenic T-cells, and 2) an Aryl Hydrocarbon Receptor (AhR) modulation platform designed for non-immunosuppressive barrier tissue repair and immunoregulation.

Itolizumab competes with JAK inhibitors and other novel agents in aGVHD and against established biologics in lupus. Its differentiation is a first-in-class CD6 target. EQ504 would enter a crowded asthma market but offers a unique, non-immunosuppressive AhR mechanism focused on barrier repair.